Posted by Michael Wonder on 27 Jul 2024
Astellas receives positive CHMP opinion for zolbetuximab in combination with chemotherapy for treatment of advanced gastric and gastro-oesophageal junction cancer
26 July 2024 - If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2 targeted therapy approved in the European Union.
Astellas today announced that on 26 July 2024, the CHMP of the EMA adopted a positive opinion recommending the approval of zolbetuximab in the European Union.
